MEDICINA
Departamento
Universidad de Navarra
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Universidad de Navarra (203)
2024
-
ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy
Blood, Vol. 143, Núm. 18, pp. 1807-1815
-
Albumin Redox Modifications Promote Cell Calcification Reflecting the Impact of Oxidative Status on Aortic Valve Disease and Atherosclerosis
Antioxidants, Vol. 13, Núm. 1
-
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
Advances in Therapy, Vol. 41, Núm. 4, pp. 1576-1593
-
Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry
Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145
-
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry
Clinical and Translational Oncology
-
Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives
Journal of the American College of Cardiology, Vol. 83, Núm. 17, pp. 1640-1651
-
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling
Haematologica, Vol. 109, Núm. 3, pp. 877-887
-
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia
American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595
-
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202
-
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Clinical and Translational Oncology
-
[Translated article] Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study
Actas Dermo-Sifiliograficas, Vol. 115, Núm. 3, pp. T237-T245
2023
-
A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study
Hematology (United Kingdom), Vol. 28, Núm. 1
-
Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 1, pp. 57-64
-
Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)
Seminars in Arthritis and Rheumatism, Vol. 58
-
Clinical description, molecular delineation and genotype-phenotype correlation in 340 patients with KBG syndrome: Addition of 67 new patients
Journal of Medical Genetics, Vol. 60, Núm. 7, pp. 644-654
-
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Blood Cancer Journal, Vol. 13, Núm. 1
-
Coronary Obstruction After Transcatheter Aortic Valve Replacement: Insights From the Spanish TAVI Registry
JACC: Cardiovascular Interventions, Vol. 16, Núm. 10, pp. 1208-1217
-
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)
Leukemia
-
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
Blood cancer journal
-
Diagnosis and Treatment of Pleural Effusion. Recommendations of the Spanish Society of Pulmonology and Thoracic Surgery. Update 2022
Archivos de Bronconeumologia, Vol. 59, Núm. 1, pp. 27-35